The FDA has issued black box warnings for four drugs used to treat different types of arthritis. This article will explain which medications have warnings and why.
Read More »Tag: arthritis
NCHR’s Testimony to FDA Regarding Tanezumab for Osteoarthritis
March 24, 2021: We agree with the FDA’s assessment that the risk mitigation measures proposed for tanezumab are not likely to be feasible or effective, and there are serious risks, even after patients discontinue use.
Read More »